• In The News

    A first in Morocco: CIPLA MAROC opens an inhaler manufacturing plant in the Rabat region for an investment of 60 MDH

    Inaugurated by MM. Anas Doukali and MM. Moulay Hafid Elalamy, the plant will produce 1.5 million metered-dose inhalers annually Rabat, Morocco, October 13, 2018: Cipla Maroc, subsidiary of the leading global pharmaceutical company Cipla Ltd, today announced the official opening of its manufacturing plant for metered-dose inhalers in Ain Aouda in the Rabat region. A […]

    November 2, 2018
  • In The News

    Child malaria deaths dramatically cut by suppository drug, shows Zambia study

    Internally administered medicine allows crucial window of time for children in remote areas to reach healthcare facilities A suppository form of a malaria-fighting drug could provide a lifeline to children in rural areas, drastically cutting the number of deaths caused by the disease. A study in rural Zambia found that suppository drugs administered by community […]

  • In The News

    Morocco Enhances Pharmaceutical Sector with New Production Facility

    Morocco inaugurated on Saturday a new metered dose inhalers’ (MDI) production facility in Ain Aouda, near Rabat. – Rabat The factory that represents a 60 MDH investment, is the first of its kind to open in Morocco, according to state-owned media outlet Maghreb Arab Press (MAP). Cipla Morocco, subsidiary of the Indian pharmaceutical group, Cipla […]

  • In The News

    Cipla, Putting Social Stigma to Rest

    Abid Hussain Barlaskar , afaqs!, New Delhi In the brand’s latest ad, Priyanka Chopra’s revelation of being an asthmatic is set to dilute the bad buzz around asthma and inhalers. Pharmaceutical company Cipla, in its latest commercial for campaign #BerokZindagi aims at dispelling stigmas around asthma and normalising the use of inhalers in everyday life. […]

  • In The News

    Cipla eyes next leg of growth from global biz

    In India, the company is by far the leader in the respiratory drugs segment, having a turnover of over Rs 18.93 billion. Sohini Das The company already enjoys a 67-68 per cent share of the respiratory drugs market in India and has potential for a 14-15 per cent growth Cipla, a prominent name in the […]